Guangdong Hybribio BiotechLtd Past Earnings Performance
Past criteria checks 2/6
Guangdong Hybribio BiotechLtd has been growing earnings at an average annual rate of 35.4%, while the Biotechs industry saw earnings growing at 8.5% annually. Revenues have been growing at an average rate of 33.6% per year. Guangdong Hybribio BiotechLtd's return on equity is 1.3%, and it has net margins of 12.7%.
Key information
35.4%
Earnings growth rate
34.3%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 33.6% |
| Return on equity | 1.3% |
| Net Margin | 12.7% |
| Next Earnings Update | 27 Apr 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Guangdong Hybribio BiotechLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,104 | 140 | 532 | 136 |
| 30 Sep 23 | 2,189 | 409 | 677 | 190 |
| 30 Jun 23 | 3,361 | 870 | 761 | 238 |
| 31 Mar 23 | 4,388 | 1,291 | 861 | 256 |
| 31 Dec 22 | 5,597 | 1,725 | 1,098 | 247 |
| 30 Sep 22 | 4,940 | 1,693 | 927 | 195 |
| 30 Jun 22 | 4,217 | 1,439 | 888 | 146 |
| 31 Mar 22 | 3,574 | 1,180 | 830 | 118 |
| 01 Jan 22 | 2,673 | 852 | 633 | 115 |
| 30 Sep 21 | 2,429 | 736 | 616 | 108 |
| 30 Jun 21 | 2,148 | 625 | 591 | 96 |
| 31 Mar 21 | 1,814 | 515 | 548 | 86 |
| 31 Dec 20 | 1,354 | 363 | 465 | 72 |
| 30 Sep 20 | 1,129 | 316 | 422 | 61 |
| 30 Jun 20 | 918 | 216 | 401 | 59 |
| 31 Mar 20 | 742 | 150 | 371 | 61 |
| 31 Dec 19 | 729 | 147 | 386 | 57 |
| 30 Sep 19 | 693 | 141 | 376 | 55 |
| 30 Jun 19 | 648 | 128 | 355 | 52 |
| 31 Mar 19 | 610 | 119 | 340 | 55 |
| 31 Dec 18 | 580 | 114 | 327 | 46 |
| 30 Sep 18 | 548 | 107 | 307 | 41 |
| 30 Jun 18 | 518 | 102 | 276 | 52 |
| 31 Mar 18 | 499 | 96 | 281 | 34 |
| 31 Dec 17 | 479 | 93 | 267 | 34 |
| 30 Sep 17 | 455 | 89 | 263 | 24 |
| 30 Jun 17 | 431 | 80 | 274 | 0 |
| 31 Mar 17 | 411 | 77 | 260 | 0 |
| 31 Dec 16 | 398 | 76 | 256 | 0 |
| 31 Dec 15 | 345 | 65 | 227 | 0 |
| 31 Dec 14 | 264 | 63 | 152 | 0 |
| 31 Dec 13 | 183 | 29 | 113 | 0 |
Quality Earnings: 300639 has high quality earnings.
Growing Profit Margin: 300639's current net profit margins (12.7%) are lower than last year (30.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300639's earnings have grown significantly by 35.4% per year over the past 5 years.
Accelerating Growth: 300639's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 300639 had negative earnings growth (-91.9%) over the past year, making it difficult to compare to the Biotechs industry average (-2.6%).
Return on Equity
High ROE: 300639's Return on Equity (1.3%) is considered low.